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AbsTrACT
Objective Previous work has established that the 
deacetylase sirtuin-1 (sirT1) is cleaved by cathepsin B 
in chondrocytes subjected to proinflammatory stress, 
yielding a stable but inactive n- terminal (nT) polypeptide 
(75sirT1) and a c- terminal (cT) fragment. The present 
work examined if chondrocyte- derived nT- sirT1 is 
detected in serum and may serve as an investigative and 
exploratory biomarker of osteoarthritis (oa).
Methods We developed a novel elisa assay to 
measure the ratio of nT to cT of sirT1 in the serum 
of human individuals and mice subjected to post- 
traumatic oa (PToa) or age- dependent oa (aDoa). 
We additionally monitored nT/cT sirT1 in mice subject 
to aDoa/PToa followed by senolytic clearance. Human 
chondrosenescent and non- senescent chondrocytes were 
exposed to cytokines and analysed for apoptosis and nT/
cT sirT1 ratio in conditioned medium.
results Wild- type mice with PToa or aDoa of 
moderate severity exhibited increased serum nT/
cT sirT1 ratio. in contrast, this ratio remained low in 
cartilage- specific Sirt1 knockout mice despite similar 
or increased PToa and aDoa severity. local clearance 
of senescent chondrocytes from old mice with post- 
traumatic injury resulted in a lower nT/cT ratio and 
reduced oa severity. While primary chondrocytes 
exhibited nT/cT ratio increased in conditioned media 
after prolonged cytokine stimulation, this increase was 
not evident in cytokine- stimulated chondrosenescent 
cells. Finally, serum nT/cT ratio was elevated in humans 
with early- stage oa.
Conclusions increased levels of serum nT/cT sirT1 
ratio correlated with moderate oa in both mice and 
humans, stemming at least in part from non- senescent 
chondrocyte apoptosis, possibly a result of prolonged 
inflammatory insult.
bACkgrOund
Articular cartilage is a thin hyaline tissue covering 
opposing bone ends in synovial joints. It prevents 
bone end erosion by absorbing mechanical loads 
inflicted by daily activities and ensures friction- less 
and pain- free joint articulation and movement.1–3 
Osteoarthritis (OA), the most prevalent degener-
ative joint disease in humans, is characterised by 
progressive deterioration and loss of articular carti-
lage. Clinical symptoms typically arise only once 
cartilage is already irreversibly destroyed. They 
include pain, radiographic features and joint effu-
sion of exposed subchondral bone.1 2
Cartilage destruction leading to OA is due to 
excessive mechanical stress to the joint and to 
proinflammatory insults that suppress the anabolic 
activities of chondrocytes and evoke catabolic activ-
ities.1 Chondrosenescence was recently cemented as 
a hallmark of OA pathogenesis, by showing that the 
clearing senescent cells from articular cartilage was 
beneficial to prevent- OA.4 5 Chondrosenescence 
key messages
What is already known about this subject?
 ► We have previously shown that SIRT1 can 
be cleaved in cartilage during osteoarthritis 
(OA) and under inflammatory conditions. It is 
also known to be detected in sera in various 
diseases, as we detail in the Discussion section 
within the manuscript text.
What does this study add?
 ► This study adds a new method for detecting 
Sirt1 cleaved variants in sera. We show that 
these variants are directly linked to cartilage 
degeneration, using our genetic mouse models 
which bear ablated Sirt1 from cartilage. These 
mouse models (ie, with ablated Sirt1 from 
cartilage) subjected to ageing or post- traumatic 
OA show reduced levels of these variants 
in sera, despite OA development. Another 
novelty is the association of these cleaved Sirt1 
variants with chondrosenesence, which has not 
been previously reported. In fact, eliminating 
chondrosenescent cells reduced Sirt1 variants in 
vitro and in vivo.
How might this impact on clinical practice or 
future developments?
 ► The data herein merit clinical studies to validate 
this serum measure for categorising and 
stratifying OA severity, which can accelerate 
drug development and personalised medicine 
for OA sufferers. Importantly, the portion 
related to chondrosenescence and senolytic 
drug administration indicate that this serum 
measure can predict senolytic drug efficiency in 
OA, which can minimise the need for imaging 
modalities to assess joint structural changes 
following drug administration, to ultimately 
develop disease- modifying OA drugs for clinical 
use.
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increases with age as well as during post- traumatic joint insults. 
It contributes to gradual tissue loss as chondrocytes exhibiting a 
senescence- associated secretory phenotype (SASP), which exude 
proinflammatory cytokines that may affect non- senescent neigh-
bouring cells.6 7
Nowadays, a main challenge in the management of OA is 
to develop disease- modifying drugs capable of halting disease 
progression, reversing tissue damage, restoring structure and 
relieving symptoms. Another major challenge is to identify effec-
tive biomarkers that meet the ‘BIPED’ biomarker classification 
criteria, established by the National Institutes of Health Osteo-
arthritis Biomarkers Network; including biomarkers for Burden 
of disease (B), Investigative (I), Prognostic (P), Efficacy of inter-
vention (E) and Diagnostic (D).8 9 Notably, while diagnostic 
markers help determine the disease stage, prognostic markers 
help predict the rate and severity of disease progression.10 11 
Such markers would be instrumental to assess optimal timing for 
candidate drug treatments and to reduce the need for imaging 
modalities (ie, MRI or X- ray).
Accumulating reports support the notion that SIRT1, a- 
nicotinamide adenine dinucleotide (NAD)- dependent enzyme 
silent information regulator 2 type 1 deacetylase, is critical in 
maintaining adult cartilage health by promoting chondrocyte 
survival and extracellular matrix (ECM) homeostasis.12 Loss of 
SIRT1 activity has been described in several age- related diseases, 
including Alzheimer’s13 as well as diabetes type 2,14 metabolic 
syndrome and obesity,15 16 and SIRT1 circulating levels have 
recently become attractive biomarkers of such conditions.17–19 
Mounting data support that SIRT1 is proteolytically inactivated 
during OA.20 21 Thus, in this study, we developed an ELISA 
assay that distinguishes a SIRT1 N- terminal polypeptide (NT) 
from SIRT1 C- terminal polypeptides (CT) in human and mouse 
serum. We used this assay to assess if serum NT/CT SIRT1 ratio 
is elevated in mice and humans with moderate OA and could 
therefore be used as a potential disease biomarker at an early, yet 
asymptomatic stage of joint deterioration.
MATeriAls And MeTHOds
Online supplementary S1 contains all sections materials and 
methods.
resulTs
development of elisA to measure the serum nT/CT sirT1 
ratio
Our group initially described a CT truncation in human and 
mouse SIRT1 carried out by cathepsin B,20 which docks to an 
unstructured loop domain of SIRT1.22 This results in a human 
75 kDa NT- intact Sirt1 polypeptide with impaired deacetylase 
activity.21–24 Based on these data, it is envisioned that NT SIRT1 
antibodies would detect both 75SIRT1 and flSIRT1 given that 
both possess intact NT domains. In 2012, a report by Chalk-
iadaki and Guarente showed that HFD resulted in NT- domain 
cleavage of Sirt1, by caspase 1, resulting in a similar 75 kDa poly-
peptide with intact CT, in inflamed adipose tissue.25 To this end, 
here, we aimed to assess both NT and CT domains of SIRT1 to 
differentiate between OA severity and other conditions related 
to fat metabolism or other unknown conditions causing an NT 
truncation.
Accordingly, we hypothesised that in OA, degenerated carti-
lage would contribute to increased NT SIRT1 in serum. This 
assay can either measure intact SIRT1 and/or SIRT1 polypep-
tides bearing either CT (aa 700-747) or NT (aa 1-131), as illus-
trated in the plate set- up in figure 1A,B, and in the predicted 
assay outcomes in figure 1C. Notably, a ratio of 1 would indicate 
equal concentrations of NT and CT SIRT1 polypeptides, which 
may not necessarily be the full molecular length of SIRT1. The 
ELISA assay was validated for reproducibility via %CV assay, 
specificity via spike in assay and linearity via dilution recovery 
(table 1) and western blot confirmed the capacity of antibodies 
to recognise full length or 75SIRT1 (online supplementary S2).
The serum nT/CT sirT1 ratio is elevated in PTOA-induced and 
aged mice
To assess if SIRT1 fragments are affected by OA, we performed 
DMM surgery on wild- type (wt) mice (CD1/129/J) to induce 
post- traumatic osteoarthritis (PTOA, figure 2A,B) and we 
also compared young (3 months) and old (15 months) mice 
(figure 2D,E). In mice with PTOA, both the tibial plateau (TP) 
and the femoral condyles (FC) showed a significant increase 
in OA severity compared with mice subjected to sham surgery 
(figure 2A,B, respectively), with severity in the mild range. While 
no difference in the serum NT/CT SIRT1 ratio was detected at 
2, 4 and 6 weeks post surgery, a significant increase of approx-
imately twofold was measured at 8 weeks in mice with DMM 
compared with controls (figure 2C, below panel illustration 
of experimental set- up). Assessing the correlation between OA 
severity and NT/CT SIRT1 ratio of individual mice (figure 2G) 
shows higher correlation values in DMM (upper panel) versus 
sham mice (middle panel), indicating that PTOA is associated 
with increased NT/CT SIRT1 ratio.
We next examined if age- induced OA causes changes in 
serum NT/CT SIRT1 ratio, by comparing 3M and 15M mice 
(figure 2D,E). The results show an approximately threefold 
increase in OA severity in the TP and FC on ageing (figure 2D), 
accompanied with an approximately fourfold increase in serum 
NT/CT SIRT1 ratio (figure 2F, below panel illustration of exper-
imental set- up). In conclusion, an increase in the serum NT/
CT SIRT1 ratio is thus associated with both early- stage PTOA 
and aging- related OA. Lower panel of figure 2G shows a signif-
icant correlation of OA severity with NT/CT SIRT1 ratios in the 
ageing mice cohort.
The serum nT/CT sirT1 ratio is elevated in human patients 
with OA
The analysis of a cohort of 28 patients (figure 3A) showed an 
increase in the serum NT/CT SIRT1 ratio in individuals with 
early OA compared with healthy donors, mostly due to higher 
NT values (NT SIRT1: p=0.0003 non- OA vs early OA; NT/CT 
SIRT1: p=0.019 non- OA vs early OA). Interestingly, NT values 
are increased in synovial fluid between healthy donors and late 
OA (SF; p=0.018; figure 3B). Correlation data of each variant 
in serum and SF shows a stronger correlation of the NT vari-
ants in serum and SF, versus CT variants (figure 3C, left and 
middle panel). Moreover, the strongest correlation (p=0.059) 
was observed for the NT/CT SIRT1 ratio when assessing serum 
and SF, using an indirect ELISA method (figure 3C, right panel). 
These data possibly indicate that NT variants can efficiently 
reach the circulation during the early stages of OA, while their 
constant production at late stages of the disease may tend to 
accumulate in SF. Cumulatively, the results support the notion 
that serum NT/CT SIRT1 ratio is predictive of early OA and may 
arise from synovial fluid.
To further assess if either NT, CT or NT/CT are associated 
with risk factors of OA, we carried out correlation assays for 
serum, which display similar significant correlations of all 
three variables to age (online supplementary S3A), and weaker 
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Figure 1 ELISA assay for N- terminal (NT)/C- terminal (CT) SIRT1 ratio. Diluted serum or conditioned media are incubated with either NT- reactive 
or CT- reactive antibodies and concentrations are calculated based on the respective standard curve. The plate configuration is added next to the 
standard curve illustration (A). Each serum sample is either incubated with an NT- reactive or CT- reactive antibody (B), wherein ratio between the NT 
and CT concentrations denoted NT/CT SIRT1 ratio. (C) Possible scenarios related to this ELISA method: (1) an equal NT and CT ratio of 1 indicates 
that there is no increase in either protein domains of SIRT1 in examined samples; (2) cleavage of both NT and CT domains will render undetected; 
(3) increased NT concentration as compared with CT concentration rendering a value over 1; (4) increased CT concentration as compared with NT 
concentration rendering a value less than 1. Notably, using this method, one cannot distinguish between full length and cleaved variants of SIRT1, 
rather NT- reactive or CT- reactive polypeptides of SIRT1.
Table 1 ELISA validation parameters
Mice sera nT antibody CT antibody Human sera nT antibody CT antibody
%CV 26.3 18.35 %CV 18.5 28.9
spike in 88.6%±9% 96%±3.5% spike in 102%±12.8% 89.8%±7.0%
dilution recovery 122%±64% 123%±19% dilution recovery 149%±18% 139%±10%











(1) Percent coefficient of variance (%CV) was calculated for N- terminal (NT) and C- terminal (CT) against mouse and human epitopes, and was calculated for five different 
serum samples in three identical plates. The mean concentration for a given samples was determined and divided by the SD. Values were then multiplied by 100 to achieve %CV 
values. (2) Dilution recovery for NT and CT against mouse and human epitopes was calculated for three different serum samples (n=3), each individually diluted 1:1000 (A) or 
1:2000 (B), which is within the working dilution range. Dilution recovery was calculated by ((A)/(B*2))*100. (3) Spike in: (a) human samples: For NT/CT antibody, the neat serum 
samples was diluted 1:5000 and spiked with 3.1 ng/mL. After calculating the protein conc. via standard curve, the neat values were subtracted from the spiked and divided by 
the expected concentration, which was multiplied by 100 to reach % spiked in recovery; (b) mouse samples spike in for NT antibodies were done in 1:3000 (neat) spiked with 
1.5 ng/mL flSirt1 (n=5). Spike in for mouse CT antibodies was done in 1:5000 (neat) spiked with 3.1 ng/mL flSirt1 (n=3). Last two rows in table include epitope recognition and 
manufacturer information.
correlations to body mass index (BMI) and OA severity. Based 
on these data, we could not conclude that one variable is prefer-
able over others for assessing OA severity. However, it appears 
that among three variables NT presented the strongest correla-
tion to OA severity (online supplementary S3A table), using an 
indirect ELISA method.
Assessing the same cohort with a sandwich ELISA method 
(online supplementary S3B,C) displayed significant increase for 
NT SIRT1 with OA severity, which was marginally significant 
for CT and NT/CT SIRT1 variants, the latter due to reduced 
sensitivity of the assay to CT SIRT1 variants. Moreover, while 
significant correlations for NT SIRT1 were found with age, BMI 
and OA severity, CT and NT/CT SIRT1 values did not correlate 
significantly with age, BMI and OA severity. The sandwich ELISA 
platform appears to favour assessment of NT variants; however, 
this remains to be fully determined with a more optimised assay 
that enables better detection of CT SIRT1 variants.
We next assessed degenerative and intact cartilage regions 
for NT and CT SIRT1 levels. We observed a more enhanced 
staining for NT- SIRT1 in degenerated zones than for CT- SIRT1 
(figure 3D), supporting that NT- SIRT1 fragments are generated 
by articular chondrocytes as OA progresses (n=5, end- stage 
OA samples). Accordingly, we previously showed that protein 
extracts from degenerated cartilage contained higher levels of 
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Figure 2 Increased N- terminal (NT)/C- terminal (CT) SIRT1 ratio is observed in moderate osteoarthritis (OA) severity in wild- type (WT) mice. WT 
(male and female) Sirt1 mice 3M were subjected to destabilisation of the medial meniscus (DMM) or sham procedures (see the Materials and 
methods section, supplemental text 1) and euthanised at 4 and 8 weeks post DMM. Joints were harvested and processed for histology (Safranin O/
Fast green staining) and ranked for OA severity based on Glasson et al30, for tibial plateau (TP) or femoral chondyle (FC). Representative sections for 
each time point are presented underneath each OA ranking diagram. (A) 4 weeks: sham, n=7; DMM, n=6. (B) 8 weeks: sham, n=8; DMM, n=10. (C) 
Indirect ELISA of serum derived from WT sham and DMM mice (time points 2, 4, 6 and 8 weeks post procedure, n=7). Below the graph is a scheme 
of the experimental set- up: (D) WT (female) Sirt1 mice 3M and 15M were euthanised, joints harvested and processed for histology (Safranin O/Fast 
green staining) and ranked for OA severity based on Glasson et al.30 (E) Representative sections for each time point (n=8). (F) Indirect ELISA of serum 
derived from 3M and 15M mice (n=6). Below the graph is a scheme of the experimental set- up. Statistical significance is indicated by an asterisk 
(*, p<0.05) based on Mann- Whitney analysis. (G) Correlations of NT/CT SIRT1 ratio versus OA severity per individual mouse within the DMM (upper 
graphs); sham (middle graph) and ageing cohorts (lower graph). Correlations are presented as Pearson’s correlation (r; 1 being the best linear fit and 
0 being the weakest fit), linear regression (r2) and p value.
75SIRT1 than intact cartilage sites.24 Taken together, these data 
indicated that chondrocytes in human OA cartilage produce 
elevated levels of NT- intact SIRT1 fragments, which are at least 
partially released in the circulation and can therefore serve as 
indicators of OA.
Chondrocyte-specific inactivation of sirt1 does not alter 
skeletal development in mice
Given that SIRT1 is a ubiquitous protein, its fragments detected 
in serum could be derived from other tissues than cartilage. 
Indeed, others have shown that the level of 75SIRT1 is detected 
in tissue undergoing endothelial senescence,26 ocular inflamma-
tion27 and macrophage activation.28 To this end, we next asked 
if the changes observed in the serum NT/CT SIRT1 ratio during 
OA progression originated from chondrocytes.
As a first step, we generated doxycycline- inducible 
chondrocyte- specific Sirt1 knockout mice (ATCCreSirt1fl/fl,29), 
which we compared with Sirt1fl/fl controls. To assess if there is a 
growth phenotype in mutant mice, we induced the embryos by 
doxycycline and confirmed that skeletal growth was unaffected 
by Sirt1 genetic ablation (online supplementary S4), as previously 
reported in Col2a1 conditional mice of Sirt1.12 Costal chondro-
cytes were isolated from embryos and confirmed for lack of Sirt1 
protein and reduced activity as compared with Sirt1fl/fl litter-
mates (online supplementary S5; panels A and B). Furthermore, 
ATCCreSirt1fl/fl and Sirt1fl/fl were grown to reach 3 months and 
induced with doxycycline for 2 weeks. SIRT1 protein levels were 
detected in brain, muscle, fat and heart tissues among the geno-
types, as observed in immunoblots (online supplementary S5C), 
supporting that recombination did not occur in these tissues and 
likely specific to cartilage, as previously reported.29
serum sirT1 variants are cartilage derived
To assess if the elevated level of serum SIRT1 fragments detected 
in humans and mice with OA is cartilage derived, we employed 
induced PTOA in our cartilage- specific Sirt1 knockout mouse 
model and analysed samples 8 weeks after DMM surgery 
(figure 4A; illustration of experimental set- up). While control 
mice developed significant OA lesions in the medial compart-
ments following DMM (figure 4B), mutant mice developed OA 
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Figure 3 Degenerating cartilage explants and patients with early osteoarthritis (OA) display elevated N- terminal (NT)/C- terminal (CT) SIRT1 ratio. 
(A) Indirect ELISA of individual human serum samples derived from patients with non- OA, early OA (outerbridge score <2) and late OA (outerbridge 
score >2), (n>9) for either NT- SIRT1, CT- SIRT1 (ng/mL) or NT/CT SIRT1 ratio. (B) Indirect ELISA of individual human synovial fluid (SF) samples derived 
from patients with non- OA (n=10), early OA (outerbridge score<2, n=9) and late OA (outerbridge score>2), (n=9) for either NT- SIRT1, CT- SIRT1 (ng/
mL) or NT/CT SIRT1 ratio. Median in black bar and average in broken black bar within the box (A–C). Whiskers represent first and third quartile sample 
values. (C) Serum and SF correlation analysis for NT, CT and NT/CT SIRT1 ratio. Correlations are presented as Pearson’s correlation (r; 1 being the best 
linear fit and 0 being the weakest fit), linear regression (r2) and p value. (D) Immunohistochemistry for NT- SIRT1 and CT- SIRT1 of OA cartilage (n=5). 
Statistical significance is indicated by an asterisk (*) (p<0.05) based on Mann- Whitney test.
lesions in all compartments of the knee (figure 4C). These lesions 
were more severe in lateral compartments in the mutant than 
control mice (figure 4D). The subchondral bone thickness and 
bone volume/tissue volume ratio did not show any significant 
variations among the genotypes post DMM (online supplemen-
tary S6). The analysis of serum showed an expected increase in 
the NT/CT SIRT1 ratio in control mice after DMM (figure 4F). 
Interestingly, this increase was not observed in mutant mice, 
which lack Sirt1 expression in chondrocytes. The analysis of the 
serum levels of SIRT1 NT and CT showed that mutant mice had 
less SIRT1 NT fragment in the circulation than control mice, 
but similar levels of CT variant (figure 4G). Figure 4H shows 
significant correlation values in DMM Sirt1fl/fl (left panel) versus 
ATCCreSirt1fl/fl mice (right panel) when comparing individual NT/
CT SIRT1 ratios to OA severity. These data thus demonstrated 
that the elevated NT/CT SIRT1 ratio in control mice developing 
PTOA was due to an increased release of NT fragment from 
chondrocytes into the serum.
Next, we compared 3.5- month- old and 16.5- month- old 
control and mutant mice for age- related OA development 
(figure 5A; illustration of experimental set- up). Both types of 
mice developed knee OA on ageing (figure 5B,C, respectively). 
Their degree of OA severity was similar, except for the lateral 
compartment, which was more affected in the old mutant than 
control mice (figure 5D). Analysis of serum showed an expected 
increase in NT/CT SIRT1 values in old control mice, which was 
not observed in old mutant mice (figure 5F). This increase was 
due to a significantly lower level of NT variant in the mutants 
rather unchanged level of CT variant (figure 5G). Figure 5H 
shows higher correlation values in 3.5- month and 16.5- month 
Sirt1fl/fl mice (left panel) versus age- matched ATCCreSirt1fl/fl mice 
(right panel) when comparing individual NT/CT SIRT1 ratios 
to OA severity. Thus, like the PTOA mouse model, the ageing 
mouse model indicated that the elevated NT/CT SIRT1 frag-
ments detected in the serum of mice with OA are derived from 
chondrocytes.
The serum nT/CT sirT1 ratio reflects local clearance of 
senescent cells
We next sought to examine if combined systemic and intra- 
articular administration of a senolytic drug would affect these 
outcomes. Such a treatment was proven efficient in clearing 
senescent chondrocytes and in limiting PTOA progression 
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Figure 4 Genetic ablation of Sirt1 in cartilage reduces the N- terminal (NT)/C- terminal (CT) SIRT1 serum ratio post DMM. (A) Scheme of the 
experimental set- up: 4- months- old Sirt1fl/fl and ATCcreSirt1fl/fl mice (C57BL/6 background) were treated as indicated in the Materials and methods 
section. They were euthanised 8 weeks post DMM and serum was collected for indirect ELISA analysis to examine NT/CT SIRT1 ratio at experimental 
endpoint (mice were euthanised at 20 weeks of age). Osteoarthritis (OA) severity ranking based on Glasson 2010 criteria was carried out for medial 
tibial plateau (MTP), lateral tibial plateau (LTP), medial femoral chondyle (MFC), lateral femoral chondyle (LFC) of the following. (B) DMM (n=8; 50% 
male) versus sham Sirt1fl/fl(n=7; 43% male). (C) DMM (n=12, 58% male) versus sham ATCcreSirt1fl/fl (n=7, 43% male). (D) DMM Sirt1fl/fl vs ATCcreSirt1fl/
fl. (E) Displays representative histological images following Safranin O/Fast green staining for each genotype and treatment. (F) NT/CT SIRT1 ratio was 
established based on indirect ELISA method for serum of Sirt1fl/fl and ATCcreSirt1fl/fl mice subject to sham or DMM procedures. (G) Individually detected 
levels of NT or CT SIRT1 variants detected in DMM- treated ATCcreSirt1fl/fl and compared with Sirt1fl/fl baseline (broken bar). Statistical significance is 
indicated by an asterisk (*, p<0.05) based on Mann- Whitney analysis. (H) Correlations of NT/CT SIRT1 ratio versus OA severity per individual mouse 
within the DMM Sirt1fl/fl (left graphs) and ATCcreSirt1fl/fl (right graph). Correlations are presented as Pearson’s correlation (r; 1 being the best linear fit 
and 0 being the weakest fit), linear regression (r2) and p value.
of 3- month mice.5 Here, we used aged mice (16 months) and 
subjected them to anterior cruciate ligament transection (ACLT) 
procedure (figure 6A; illustration of experimental set- up). Similar 
to previous data with 3- month mice,5 representative depictions 
of histopathology show that vehicle- treated ACLT mice devel-
oped OA within 4 weeks (figure 6B), while systemic and local 
administration of ABT263 and UBX0101, respectively, exhib-
ited OA severity levels comparable to sham surgery (currently 
under review). In fact, OA severity was significantly increased 
(threefold) in vehicle- treated ACLT mice versus sham controls 
(unshown), based on Glasson et al grading method.30 More-
over, senolytic- treated mice and sham controls showed similar 
OA severities, which were found to be statistically insignificant 
(unshown). Importantly, NT/CT SIRT1 ratio was significantly 
increased in vehicle- treated ACLT mice, as previously observed 
in the DMM model (figures 2 and 4). Interestingly, ACLT mice 
treated with the senolytic drug had a lower NT/CT SIRT1 
ratio, which correlated with reduced OA severity (figure 6C). 
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Figure 5 Ablation of Sirt1 in cartilage reduced N- terminal (NT)/C- terminal (CT) SIRT1 ratio in serum of aged versus young mice. (A) Scheme of the 
experimental set- up: wild- type (WT) Sirt1fl/fl and ATCcreSirt1fl/fl mice (C57BL/6 background) were treated as detailed in the Materials and methods 
section and euthanised at 3.5 and 16.5 months. Following sacrifice, osteoarthritis (OA) severity ranking was carried out based on joint sections 
stained with Safranin O/Fast green staining and subsequently graded using Glasson 2010 criteria for medial tibial plateau (MTP), lateral tibial 
plateau (LTP), medial femoral chondyle (MFC) and lateral femoral chondyle (LFC) of the following. (B) 3.5 (n=5, 40% male) versus 16.5 (n=7, 0% 
male) months Sirt1fl/+. (C) 3.5 (n=5, 60% male) versus 16.5 (n=13, 100% male) months ATCcreSirt1fl/fl and (D) 16.5 months Sirt1fl/fl versus 16.5 months 
ATCcreSirt1fl/fl. (E) Representative histological images (Safranin O/Fast green staining) for each genotype and treatment. (F) NT/CT SIRT1 ratio was 
established based on the indirect ELISA method for serum of Sirt1fl/fl and ATCcreSirt1fl/fl mice subject to sham or DMM procedures. (G) Individually 
detected levels of NT Sirt1 or CT Sirt1 variants for old (16.5 months) ATCcreSirt1fl/fl and compared with Sirt1fl/fl baseline (broken bar). Statistical 
significance is indicated by an asterisk (*, p<0.05) based on Mann- Whitney analysis. (H) Correlations of NT/CT SIRT1 ratio versus OA severity per 
individual mouse within the 3.5 months and 16.5 months Sirt1fl/fl (left graphs) and age- matched ATCcreSirt1fl/fl (right graph). Correlations are presented 
as Pearson’s correlation (r; 1 being the best linear fit and 0 being the weakest fit), linear regression (r2) and p value.
The serum levels of both NT and CT dropped after senolytic 
treatment, with a sharper drop (10- fold) for NT than for CT 
(twofold; figure 6D) values.
Immunohistochemistry of cartilage tissue sections showed a 
twofold reduction of NT- SIRT1 staining in vehicle- treated ACTL 
versus sham mice (figure 6E,F). Senolytic clearance resulted in an 
increase in the cellular NT- SIRT1 levels compared with vehicle, 
a trend similar to that observed in younger mice (3.5 months; 
online supplementary S7A). To further assess the link between 
senescence and Sirt1, we examined ATCCreSirt1fl/fl and Sirt1fl/fl 
post- DMM (online supplementary S7B,C). Results show that 
DMM contributed to the appearance of p16INK4a (online supple-
mentary S7B) in articular chondrocytes, versus sham controls. 
When comparing post- DMM articular cartilage from Sirt1fl/fl to 
ATCCreSirt1fl/fl, it appeared that p16INK4a positive chondrocytes 
were more abundant in ATCCreSirt1fl/fl mice (online supplemen-
tary S7B), supporting the concept that lack of SIRT1 promotes 
senescence, in line with other reports.31 32 The data also confirm 
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Figure 6 Post- traumatic ACLT- induced osteoarthritis (OA) augments the serum SIRT1 N- terminal (NT)/C- terminal (CT) Sirt1 which were reduced 
following intra- articular (IA) senolytic administration. (A) Scheme of the experimental set- up; C57B6 mice at age 16 months were subjected to ACLT 
procedure and treated 7 days post ACLT with 5 consecutive intraperitoneal injections of ABT263, followed by 6 IA injections every other day until 
sacrifice 28 days post surgery. (B) Representative images of joints stained with Safranin O/Fast green from A (n=4 for each group, ×10 magnification). 
(C) NT/CT SIRT1 ratio was established based on the indirect ELISA method for serum of mice in A. (D) Individual levels of NT or CT for mice in A (n=4) 
normalised to the sham mice. (E) Immunohistochemistry for NT- SIRT1 of ACLT- senolytic treated mice (n=3), ACLT- vehicle treated mice (n=3) and sham 
mice (n=4). (F) Quantification of SIRT1- positive nuclei from total cell population per field, in immunohistochemical sections.
that administration of senolytic drugs effectively cleared senes-
cent chondrocytes, given that SIRT1 was detected in cells only 
post treatment (figure 6E,F).
In line with previous observations, the data support that the 
NT SIRT1 variants detected in serum are derived from damaged 
cartilage, since their levels were increased in serum and simul-
taneously reduced in cartilage during ACLT. However, ACLT 
with senolytic treatment reduced the serum NT/CT SIRT1 ratio 
and increased the cellular SIRT1 level in articular cartilage. The 
data support that post traumatic insults induced chondrosenes-
cence and reduced SIRT1 levels in chondrocytes, possibly due 
to local proinflammatory signals derived from senescent cells 
releasing SASP vesicles, which have been shown to contain a 
host proinflammatory mediator, chemokines (interleukin (IL) 
1α, IL6, CXCL-8),33 34 that elicit tissue damage.35 36 While we 
did not test the presence of SASP vesicles in our report, we 
envisage that prolonged exposure to SASP may trigger apoptosis 
of non- senescent cells, resulting in fewer SIRT1- positive cells in 
articular cartilage. This consequents in increased NT/CT SIRT1 
ratio in the circulation.
long-term exposure of chondrocytes to proinflammatory 
cytokines causes cell apoptosis and the release of soluble 
sirT1 fragments
To further understand the cellular dynamics leading to the 
increase in the NT/CT SIRT1 ratio in the serum of patients with 
OA, we cultured human chondrocytes, stimulated them for 2 or 
8 days with tumour necrosis factor alpha (TNFα) and interleukin 
1β (IL1β), and assessed cell apoptosis and the NT/CT SIRT1 
ratio in conditioned medium. The rate of cell apoptosis was 
fourfold higher at day 8 than day 2 exposure and this result coin-
cided with a threefold increase in the NT/CT SIRT1 ratio (online 
supplementary S8A,B). Cell lysates revealed a significantly 
higher level of 75SIRT1 in cells stimulated with the cytokines for 
2 days but not in cells treated for 8 days (online supplementary 
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Figure 7 Non- senescent (NS) apoptotic chondrocytes contribute to N- terminal (NT)/C- terminal (CT) SIRT1 ratio in conditioned media. Human 
chondrocytes were induced to undergo senescence via actinomycin D (ACTD) and thereafter treated for 8 days with cytokines (50 ng/mL tumour 
necrosis factor alpha and 5 ng/mL interleukin 1β, denoted as ‘cytokine’). (A) Quantification of β-galactosidase positive chondrocytes (n=5). (B) 
FACS analysis for annexin V positive cells for ACTD- induced cells treated with cytokines (n=5, upper graphs) and ACTD- uninduced cells treated with 
cytokines for 8 days (n=4, lower graphs). (C) Indirect ELISA for NT/CT SIRT1 in conditioned media derived from ACTD- pretreated chondrocytes (with or 
without cytokine stimulation) and ACTD- untreated NS chondrocytes stimulated with cytokines for 8 days (n=4). *p<0.05; **p<0.001 for differences 
of ACTD cytokine (black triangles) treated and untreated (white triangles) conditioned media versus cytokine stimulated conditioned media from 
chondrocytes uninduced with ACTD (grey triangles; that is, non- senescent or ‘NS’).(D) Immunoblots for NT Sirt1 and P21 for cells in A (n=3). Statistical 
significance was determined for p<0.05 via Mann and Whitney test. (E) High 75SIRT1/CytoC cellular ratio in chondrosenescence leading to survival 
under prolonged inflammatory insult. Under such a scenario, SIRT1 variants will not be detected in conditioned media. (F) Low 75SIRT1/CytoC cellular 
ratio in NS chondrocytes leading to apoptosis under prolonged inflammatory insult (ie, cytokine). Under such a scenario, SIRT1 variants will be 
detected in conditioned media.
S8C). These data suggest that the increased rate of cell apoptosis 
observed during 8 days of cytokine insult resulted in the release 
of 75SIRT1 to conditioned medium (online supplementary S8B).
Since senescent chondrocytes are often capable of surviving 
harsh stress conditions, we postulated that by inducing chon-
drosenescence, cell death would be impaired and would conse-
quent in lower levels of NT/CT SIRT1 ratio, during prolonged 
proinflammatory exposure. We therefore induced chondrosenes-
cence with ACTD, as previously described, and confirmed cell 
senescence using a β-galactosidase staining assay (online supple-
mentary S8D). Interestingly, the numbers of β-galactosidase- 
positive cells were similar in cytokine- treated and untreated cells 
(figure 7A). In line with these observations, the percentages of 
annexin V- positive cells, as measured by fluorescence- activated 
cell sorting, did not rise on cytokine treatment (figure 7B, upper 
graph), whereas they increased fourfold for non- senescent chon-
drocytes (ie, uninduced by ACTD; lower graph of figure 7B). 
Similarly, conditioned media did not show differences in NT/CT 
SIRT1 ratio between cytokine- treated and untreated senescent 
chondrocytes (figure 7C), while non- senescent cytokine- treated 
chondrocytes showed a fourfold increase in apoptosis and a 
significant increase in NT/CT SIRT1 ratio in conditioned media. 
Analysis of adherent chondrocytes by immunoblotting showed 
similar levels of cyclin- dependent kinase inhibitor 1 (P21 level) 
confirming that ACTD rendered cell cycle arrest in both cytokine 
treated and untreated chondrocytes (figure 7D), in consistence 
with β-galactosidase staining (figure 7A). Moreover, chondro-
senscent cells did not exhibit significant changes in intracellular 
levels of 75SIRT1 following cytokine treatment (figure 7D). 
These data indicate that senescent chondrocytes may not be 
affected by cytokine insult and less likely to exhibit lysosomal 
permeability compared to non- senescent chondrocytes exposed 
to similar conditions.
The illustration in figure 7E displays a senescent chondro-
cyte wherein the inflammatory insult will induce Sirt1 cleavage 
(ie, 75SIRT1 generation), yet given that the mitochondria are 
impermeable with limited cytochrome C (CytoC) release (ie, 
high cellular 75SIRT1/CytoC ratio), the cell will remain viable; 
hence, SIRT1 variants are undetected in surrounding media 
(figure 7E). On the other hand (figure 7F), non- senescent chon-
drocytes, subject to prolonged proinflammatory exposure, will 
generate 75SIRT1 and continuously release CytoC within the 
cytoplasm (ie, low cellular 75SIRT1/CytoC). Excessive CytoC 
levels will allow apoptosome assembly, and enhance apoptosis 
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(online supplementary S8.21 Apoptotic chondrocytes (mostly 
non- senescent) will release their content, enabling the detec-
tion of SIRT1 variants in surrounding media. Finally, we argue 
that senescent chondrocytes are often fewer than non- senescent 
chondrocytes in cartilage; hence, their elimination via senolytic 
agents will not cause an increase in circulating SIRT1 variants, in 
line with our observations in figure 6. This highlights the poten-
tial value of SIRT1 and its fragments as biomarkers suitable for 
screening for novel senolytics.
disCussiOn
Recent reports have indicated that SIRT1 can be detected in 
the serum of patients with various pathologies, such as fatty 
liver disease,37 obesity,18 chronic obstructive pulmonary disease 
(COPD)38 and Alzheimer’s disease.39 Specifically, the serum level 
of SIRT1 declines in patients suffering from frailty (sarcopenia; 
cognitive decline; abnormal immune function and neuroendo-
crine systems; and poor energy regulation,40), COPD, meta-
bolic instability and Alzheimer’s disease. These data are rather 
surprising since SIRT1 is an intracellular deacetylase and it is 
mainly nuclear.
Despite accumulating data on SIRT1 in the circulation, our 
study is the first one to analyse the levels of SIRT1 variants in 
serum. Given that two truncation events have been reported 
for SIRT1, such an assay may enable better distinction between 
various conditions, such as obesity and inflammatory condi-
tions.20 25 While NT truncation via caspase 1 was correlated 
with metabolic syndrome and adipose inflammation,25 CT via 
cathepsin B was associated with joint inflammation, as well as 
other acute inflammatory conditions.20 27 28 41 Therefore, we 
opted to examine the NT/CT SIRT1 ratio, assuming that an 
increase in this ratio could indicate a local inflammatory response 
in joint cartilage, due to the presence of IL1β and TNFα, which 
have both been implicated to promote SIRT1 cleavage in carti-
lage.20 21 Notably, variants resulting from both NT and CT trun-
cation events could not be detected in our ELISA assay, since 
such variants would lack the domains detected by the antibodies 
employed.
The increase seen in NT/CT SIRT1 ratio was observed in 
moderately severe OA resulting from ageing or joint trauma 
in mouse models and human samples. Moreover, local admin-
istration of a senolytic drug reduced the serum NT/CT SIRT1 
ratio, indicating that there is a link between cell senescence 
and gradual loss of SIRT1 in cartilage during OA. These data 
strongly suggest that the serum NT/CT SIRT1 ratio may be an 
effective marker of disease severity as well as senolytic drug effi-
cacy. While this biomarker is largely investigative in this report 
with a small human cohort, the results here support that it may 
serve as a clinical biomarker for OA- related ‘Burden of Disease’ 
and/or ‘Efficacy of Intervention’ at least for senolytic drugs, in 
accordance to BIPED criteria.8
Given that SIRT1 is ubiquitously expressed and cleaved in 
cells present in other inflamed tissues, such as endothelial cells, 
macrophages and lymph node cells,26–28 it was important to 
assess if indeed serum fragments were cartilage derived. Using 
a transgenic model, with specific inactivation of Sirt1 in carti-
lage, we were able to reduce the increase in the serum NT/CT 
SIRT1 ratio associated with post- traumatic or age- induced OA. 
To further understand the mechanism by which SIRT1 fragments 
emerge in serum, we assessed conditioned media and apoptotic 
rates of cytokine- exposed chondrocytes. Interestingly, chondro-
cytes challenged with cytokines underwent increased apoptosis, 
which was accompanied with an increase in the NT/CT SIRT1 
ratio in conditioned medium. On the other hand, chondrocytes 
undergoing senescence and subsequently exposed to long- term 
cytokine insult did not show any changes in apoptotic rates or 
soluble NT/CT SIRT1 ratio. These data are consistent with the 
proinflammatory effect bestowed by SASP vesicles released from 
senescent cells.33–35 SASP particles released by senescent cells can 
induce ECM degradation and cell death and can attract immune 
cells and promote metastasis.35 36 SASP- secreting senescent cells 
bestow a ‘bystander effect’ onto neighbouring cells,42 43 creating 
a harsh environment for non- senescent cells.34 44 45
Mechanistically, we speculate that the rise in serum NT/CT 
SIRT1 ratio is closely correlated with early proinflammatory 
events in the joint since this stage is also accompanied with a rise 
in p16INK4A- positive cells following joint trauma.5 Increased chon-
drosenescence gradually contributes to a loss of non- senescent 
chondrocytes, which results in rising levels of the serum NT/
CT SIRT1 ratio. Notably, this is a direct response to prolonged 
inflammatory stress wherein accumulated 75SIRT1 is incapable 
of sufficiently binding all released CytoC to prevent cell death, 
under these harsh proinflammatory tissue conditions.21 More-
over, given that senescent cells do not show a significant increase 
in 75SIRT1 following inflammatory stimuli may indicate that 
their lysosomes are less leaky than in non- senescent cells under 
the same conditions46 and similar to mitochondria of senescent 
cells.47 Under these conditions, it is not surprising that local 
administration of senolytic drugs to eliminate surviving senes-
cent cells from cartilage ultimately reduced the serum NT/CT 
SIRT1 ratio which was likely stemming from non- senescent by 
standard chondrocytes. While these data must be further vali-
dated with a clinical grade method and using larger cohorts of 
patients, we here provide preliminary supporting evidence that 
the serum NT/CT SIRT1 ratio is indicative of early- stage OA and 
senolytic drug efficacy.
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